Insmed (NASDAQ:INSM) Price Target Raised to $90.00 at HC Wainwright

Insmed (NASDAQ:INSM) had its price objective hoisted by HC Wainwright from $70.00 to $90.00 in a report released on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Insmed’s FY2025 earnings at ($3.36) EPS, FY2026 earnings at ($1.92) EPS, FY2027 earnings at $0.14 EPS and FY2028 earnings at $2.14 EPS.

A number of other analysts have also recently weighed in on INSM. Cantor Fitzgerald restated an overweight rating on shares of Insmed in a report on Thursday, June 20th. Mizuho boosted their target price on Insmed from $36.00 to $82.00 and gave the company a buy rating in a research note on Friday, June 7th. Stifel Nicolaus increased their price objective on Insmed from $39.00 to $67.00 and gave the company a buy rating in a report on Friday, May 31st. Wells Fargo & Company upped their price target on Insmed from $55.00 to $77.00 and gave the stock an overweight rating in a report on Wednesday, May 29th. Finally, JPMorgan Chase & Co. upped their target price on Insmed from $55.00 to $72.00 and gave the company an overweight rating in a research note on Thursday, June 20th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of Moderate Buy and an average price target of $71.88.

Insmed Trading Up 5.4 %

Shares of NASDAQ:INSM opened at $77.03 on Monday. The company has a 50 day moving average of $50.32 and a 200-day moving average of $35.59. The firm has a market cap of $11.45 billion, a P/E ratio of -14.73 and a beta of 1.16. Insmed has a twelve month low of $20.01 and a twelve month high of $77.26.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.06) EPS for the quarter, topping the consensus estimate of ($1.22) by $0.16. The firm had revenue of $75.50 million for the quarter, compared to the consensus estimate of $77.76 million. Insmed’s revenue for the quarter was up 15.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.17) EPS. Equities research analysts forecast that Insmed will post -4.71 EPS for the current year.

Insiders Place Their Bets

In other news, insider John Drayton Wise sold 5,088 shares of the firm’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $25.47, for a total value of $129,591.36. Following the completion of the sale, the insider now directly owns 123,259 shares in the company, valued at $3,139,406.73. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Insmed news, insider John Drayton Wise sold 5,088 shares of the company’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $25.47, for a total transaction of $129,591.36. Following the transaction, the insider now owns 123,259 shares of the company’s stock, valued at approximately $3,139,406.73. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Martina M.D. Flammer sold 21,195 shares of Insmed stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $55.00, for a total value of $1,165,725.00. Following the completion of the sale, the insider now owns 106,134 shares of the company’s stock, valued at $5,837,370. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 295,842 shares of company stock valued at $13,762,062. 4.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Insmed

Several institutional investors have recently modified their holdings of the stock. International Assets Investment Management LLC acquired a new position in Insmed in the fourth quarter valued at about $25,000. EntryPoint Capital LLC bought a new stake in Insmed during the first quarter worth $33,000. Fidelis Capital Partners LLC acquired a new stake in Insmed in the 1st quarter valued at about $34,000. Headlands Technologies LLC bought a new position in shares of Insmed during the 1st quarter worth approximately $59,000. Finally, CWM LLC increased its holdings in shares of Insmed by 11.0% in the second quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 155 shares during the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.